Clinical Trial Management System (CTMS) Market Forecast to 2028 - Covid-19 Impact and Global Analysis - By Component (Software and Services), Product (Enterprise Based and Site Based), Delivery Mode (Web Based, Cloud Based and On Premise), End-user (Pharmaceutical & Biopharmaceutical Companies, Clinical Research Organizations [CROs], Medical Device Companies, and Other End Users), and Geography
Report Code: TIPHC00002241 | No. of Pages: 150 | Category: Healthcare IT | Status: Upcoming
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Clinical Trial - By Phase
1.3.2 Clinical Trial - By Study Design
1.3.3 Clinical Trial - By Indication
1.3.4 Clinical Trial - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. CLINICAL TRIAL LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. CLINICAL TRIAL - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. CLINICAL TRIAL - GLOBAL MARKET ANALYSIS
6.1. CLINICAL TRIAL - GLOBAL MARKET OVERVIEW
6.2. CLINICAL TRIAL - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. CLINICAL TRIAL - REVENUE AND FORECASTS TO 2028 – PHASE
7.1. OVERVIEW
7.2. PHASE MARKET FORECASTS AND ANALYSIS
7.3. PHASE I
7.3.1. Overview
7.3.2. Phase I Market Forecast and Analysis
7.4. PHASE II
7.4.1. Overview
7.4.2. Phase II Market Forecast and Analysis
7.5. PHASE III
7.5.1. Overview
7.5.2. Phase III Market Forecast and Analysis
7.6. PHASE IV
7.6.1. Overview
7.6.2. Phase IV Market Forecast and Analysis
8. CLINICAL TRIAL - REVENUE AND FORECASTS TO 2028 – STUDY DESIGN
8.1. OVERVIEW
8.2. STUDY DESIGN MARKET FORECASTS AND ANALYSIS
8.3. INTERVENTIONAL
8.3.1. Overview
8.3.2. Interventional Market Forecast and Analysis
8.4. OBSERVATIONAL
8.4.1. Overview
8.4.2. Observational Market Forecast and Analysis
8.5. EXPANDED ACCESS
8.5.1. Overview
8.5.2. Expanded access Market Forecast and Analysis
9. CLINICAL TRIAL - REVENUE AND FORECASTS TO 2028 – INDICATION
9.1. OVERVIEW
9.2. INDICATION MARKET FORECASTS AND ANALYSIS
9.3. AUTOIMMUNE/INFLAMMATION
9.3.1. Overview
9.3.2. Autoimmune/inflammation Market Forecast and Analysis
9.4. PAIN MANAGEMENT
9.4.1. Overview
9.4.2. Pain management Market Forecast and Analysis
9.5. ONCOLOGY
9.5.1. Overview
9.5.2. Oncology Market Forecast and Analysis
9.6. CNS CONDITION
9.6.1. Overview
9.6.2. CNS condition Market Forecast and Analysis
9.7. DIABETES
9.7.1. Overview
9.7.2. Diabetes Market Forecast and Analysis
9.8. OBESITY
9.8.1. Overview
9.8.2. Obesity Market Forecast and Analysis
9.9. CARDIOVASCULAR
9.9.1. Overview
9.9.2. Cardiovascular Market Forecast and Analysis
9.10. OTHERS
9.10.1. Overview
9.10.2. Others Market Forecast and Analysis
10. CLINICAL TRIAL REVENUE AND FORECASTS TO 2028 – GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Clinical Trial Overview
10.1.2 North America Clinical Trial Forecasts and Analysis
10.1.3 North America Clinical Trial Forecasts and Analysis - By Phase
10.1.4 North America Clinical Trial Forecasts and Analysis - By Study Design
10.1.5 North America Clinical Trial Forecasts and Analysis - By Indication
10.1.6 North America Clinical Trial Forecasts and Analysis - By Countries
10.1.6.1 United States Clinical Trial
10.1.6.1.1 United States Clinical Trial by Phase
10.1.6.1.2 United States Clinical Trial by Study Design
10.1.6.1.3 United States Clinical Trial by Indication
10.1.6.2 Canada Clinical Trial
10.1.6.2.1 Canada Clinical Trial by Phase
10.1.6.2.2 Canada Clinical Trial by Study Design
10.1.6.2.3 Canada Clinical Trial by Indication
10.1.6.3 Mexico Clinical Trial
10.1.6.3.1 Mexico Clinical Trial by Phase
10.1.6.3.2 Mexico Clinical Trial by Study Design
10.1.6.3.3 Mexico Clinical Trial by Indication
10.2. EUROPE
10.2.1 Europe Clinical Trial Overview
10.2.2 Europe Clinical Trial Forecasts and Analysis
10.2.3 Europe Clinical Trial Forecasts and Analysis - By Phase
10.2.4 Europe Clinical Trial Forecasts and Analysis - By Study Design
10.2.5 Europe Clinical Trial Forecasts and Analysis - By Indication
10.2.6 Europe Clinical Trial Forecasts and Analysis - By Countries
10.2.6.1 Germany Clinical Trial
10.2.6.1.1 Germany Clinical Trial by Phase
10.2.6.1.2 Germany Clinical Trial by Study Design
10.2.6.1.3 Germany Clinical Trial by Indication
10.2.6.2 France Clinical Trial
10.2.6.2.1 France Clinical Trial by Phase
10.2.6.2.2 France Clinical Trial by Study Design
10.2.6.2.3 France Clinical Trial by Indication
10.2.6.3 Italy Clinical Trial
10.2.6.3.1 Italy Clinical Trial by Phase
10.2.6.3.2 Italy Clinical Trial by Study Design
10.2.6.3.3 Italy Clinical Trial by Indication
10.2.6.4 Spain Clinical Trial
10.2.6.4.1 Spain Clinical Trial by Phase
10.2.6.4.2 Spain Clinical Trial by Study Design
10.2.6.4.3 Spain Clinical Trial by Indication
10.2.6.5 United Kingdom Clinical Trial
10.2.6.5.1 United Kingdom Clinical Trial by Phase
10.2.6.5.2 United Kingdom Clinical Trial by Study Design
10.2.6.5.3 United Kingdom Clinical Trial by Indication
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Clinical Trial Overview
10.3.2 Asia-Pacific Clinical Trial Forecasts and Analysis
10.3.3 Asia-Pacific Clinical Trial Forecasts and Analysis - By Phase
10.3.4 Asia-Pacific Clinical Trial Forecasts and Analysis - By Study Design
10.3.5 Asia-Pacific Clinical Trial Forecasts and Analysis - By Indication
10.3.6 Asia-Pacific Clinical Trial Forecasts and Analysis - By Countries
10.3.6.1 Australia Clinical Trial
10.3.6.1.1 Australia Clinical Trial by Phase
10.3.6.1.2 Australia Clinical Trial by Study Design
10.3.6.1.3 Australia Clinical Trial by Indication
10.3.6.2 China Clinical Trial
10.3.6.2.1 China Clinical Trial by Phase
10.3.6.2.2 China Clinical Trial by Study Design
10.3.6.2.3 China Clinical Trial by Indication
10.3.6.3 India Clinical Trial
10.3.6.3.1 India Clinical Trial by Phase
10.3.6.3.2 India Clinical Trial by Study Design
10.3.6.3.3 India Clinical Trial by Indication
10.3.6.4 Japan Clinical Trial
10.3.6.4.1 Japan Clinical Trial by Phase
10.3.6.4.2 Japan Clinical Trial by Study Design
10.3.6.4.3 Japan Clinical Trial by Indication
10.3.6.5 South Korea Clinical Trial
10.3.6.5.1 South Korea Clinical Trial by Phase
10.3.6.5.2 South Korea Clinical Trial by Study Design
10.3.6.5.3 South Korea Clinical Trial by Indication
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Clinical Trial Overview
10.4.2 Middle East and Africa Clinical Trial Forecasts and Analysis
10.4.3 Middle East and Africa Clinical Trial Forecasts and Analysis - By Phase
10.4.4 Middle East and Africa Clinical Trial Forecasts and Analysis - By Study Design
10.4.5 Middle East and Africa Clinical Trial Forecasts and Analysis - By Indication
10.4.6 Middle East and Africa Clinical Trial Forecasts and Analysis - By Countries
10.4.6.1 South Africa Clinical Trial
10.4.6.1.1 South Africa Clinical Trial by Phase
10.4.6.1.2 South Africa Clinical Trial by Study Design
10.4.6.1.3 South Africa Clinical Trial by Indication
10.4.6.2 Saudi Arabia Clinical Trial
10.4.6.2.1 Saudi Arabia Clinical Trial by Phase
10.4.6.2.2 Saudi Arabia Clinical Trial by Study Design
10.4.6.2.3 Saudi Arabia Clinical Trial by Indication
10.4.6.3 U.A.E Clinical Trial
10.4.6.3.1 U.A.E Clinical Trial by Phase
10.4.6.3.2 U.A.E Clinical Trial by Study Design
10.4.6.3.3 U.A.E Clinical Trial by Indication
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Clinical Trial Overview
10.5.2 South and Central America Clinical Trial Forecasts and Analysis
10.5.3 South and Central America Clinical Trial Forecasts and Analysis - By Phase
10.5.4 South and Central America Clinical Trial Forecasts and Analysis - By Study Design
10.5.5 South and Central America Clinical Trial Forecasts and Analysis - By Indication
10.5.6 South and Central America Clinical Trial Forecasts and Analysis - By Countries
10.5.6.1 Brazil Clinical Trial
10.5.6.1.1 Brazil Clinical Trial by Phase
10.5.6.1.2 Brazil Clinical Trial by Study Design
10.5.6.1.3 Brazil Clinical Trial by Indication
10.5.6.2 Argentina Clinical Trial
10.5.6.2.1 Argentina Clinical Trial by Phase
10.5.6.2.2 Argentina Clinical Trial by Study Design
10.5.6.2.3 Argentina Clinical Trial by Indication
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. CLINICAL TRIAL , KEY COMPANY PROFILES
12.1. IQVIA
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. PAREXEL INTERNATIONAL CORPORATION
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. CHARLES RIVER LABORATORY
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. ICON PLC
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. WUXI APPTEC INC
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. PRA HEALTH SCIENCES
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. SGS SA
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. SYNEOS HEALTH
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. CHILTERN INTERNATIONAL LTD
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
1. Oracle
2. Medidata Solutions Inc.
3. PAREXEL International Corporation.
4. MedNet Solutions, Inc.
5. Bioclinica
6. BioOptronics, Inc.
7. DATATRAK Int.
8. ERT Clinical
9. FORTE
10. ICON plc
Get the Latest COVID-19 Analysis on this market
Have a question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
-
$3000
-
$4550
-
$6550
-
$8550
-
Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.
Inquire for Discount